In the night before thanksgiving 2011. Amgen decided to drop a bomb on the biosimilar companies – We extent the patent for 17 years.

Most of the biosimilar companies already have put a lot of money into this drug, and I hope they will have a back up plan. I think most of them will take the approach of pull the trigger first, and the question later. Alternatively,  they freeze down their cell line, and just wait till 2028.

The IN VIVO Blog: Hopes Dashed For Biosimilar Enbrel?

The IN VIVO Blog: Hopes Dashed For Biosimilar Enbrel?.

Advertisements